Connect Biopharma (NASDAQ: CNTB) — Perfil da empresa, notícias e dados financeiros
Connect Biopharma is a biopharmaceutical company developing therapies for autoimmune diseases with a focus on innovative compounds.

Connect Biopharma
Connect Biopharma Holdings (NASDAQ:CNTB) is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of autoimmune diseases and inflammation. With a global presence, Connect Biopharma is dedicated to advancing a pipeline of novel compounds, aiming to transform patient care in areas with significant unmet medical need. The firm's hefty commitment to research and development has led to promising projects, notably in advancing treatments targeting key checkpoints in immune response pathways. The primary objective of Connect Biopharma is to leverage its proprietary technology platforms to accelerate the development of breakthrough treatments that can offer better outcomes for patients worldwide.
Resumo
Operações
Produtos e/ou serviços de Connect Biopharma
- CBP-201, an investigational antibody targeting IL-4R for treating inflammatory diseases such as atopic dermatitis and asthma.
- CBP-307, a novel small molecule modulator of S1P1 receptor, aimed at treating autoimmune diseases like ulcerative colitis and Crohn's disease.
- CBP-174, an antagonist targeting Histamine H4 receptor, developed for addressing pruritus associated with atopic dermatitis.
- CBP-233, an oral IL-4R inhibitor, designed for systemic treatment of allergic diseases.
equipe executiva do Connect Biopharma
- Barry David QuartCEO & Director
- David L. SzekeresPresident
- Lisa PerazaSenior Vice President of Finance
- Jeff CohnGeneral Counsel & Corporate Secretary
- Sean T. RistineVice President of Human Resources
- Lei SunVP of Biologics & Head of CMC
- Srikanth PendyalaSenior Vice President of Clinical Development(Consultant)
- Kimberly J. ManhardExecutive VP & Chief Development Officer
Principais indicadores financeiros
Resultados divulgados pela Connect Biopharma, em USD.
- Cap. de mercado
- 53,1 mi
- Receita (TTM)
- 3 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 64 mil | -58,1 mi | -55,5 mi | |
| 26 mi | -22,5 mi | -15,6 mi | |
| 0 | -69,1 mi | -62,1 mi | |
| 0 | -119,3 mi | -118,1 mi |